Oclacitinib
4 Inquiries
1208319-26-9
1kg
2022-02-28
chemicals,Pharmaceutical intermediates,API
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionBasic Info
-
Product Name:
Oclacitinib
Other Name:Oclacitinib PF-03394197;trans-N-Methyl-4-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-cyclohexanemethanesulfonamide;CyclohexaneMethanesulfonaMide, N-Methyl-4-(Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMino)-, trans-;N-methyl-1-((1r,4r)-4-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide;N-Methyl-1-(trans-4-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide;Oclacitinib;PF 03394197;Oclacitinib?, >98%
CAS No.:1208319-26-9
Molecular Formula:C15H23N5O2S
InChIKeys:HJWLJNBZVZDLAQ-HAQNSBGRSA-N
Molecular Weight:337.44
EC Number:950-980-7
Color/Form:Off-White to Pale Beige
Categories:
Characteristics-
Density:
1.316±0.06 g/cm3(Predicted)
Melting Point:226-228°C
Vapor Pressure:0Pa at 20-25℃
PKA:11.59±0.40(Predicted)
Critical Temperature & Pressure:Refrigerator, Under inert atmosphere
Hazard IdentificationClassification of the substance or mixture
no data available
GHS label elements, including precautionary statements
Pictogram(s) no data available Signal word no data available
Hazard statement(s) no data available
Precautionary statement(s) Prevention no data available
Response no data available
Storage no data available
Disposal no data available
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Distributor
-
Main Products:
chemicals,Pharmaceutical intermediates,API
-
Location:
No.79 Xueyuan Road, Yuhua District, Shijiazhuang City, Hebei Province
-
Payment Terms:
L/C
-
Average lead Time:
100
-
Total Annual Revenue:
Less than $1 million
-
Year of Establishment:
2020
-
-
Inquiry History4 Inquiries
Country Product Purchase Quantity Date Posted 
Germany
Oclacitinib
10 MT Jan 27, 2026 
New Zealand
Oclacitinib
1 KG May 21, 2024 
United States
Oclacitinib
10 MG Jul 1, 2025 
Bangladesh
Butyl Acetate
1.00 KG Nov 11, 2025 Post an enquiry for this product